CytRx Corporation, a biopharmaceutical company, appointed Daniel Levitt, the company's current EVP and chief medical officer, to the newly created role of chief operating officer.
Going forward, Dr. Levitt will continue to serve as CytRx's Chief Medical Officer, a role he has held in since joining CytRx in 2009.

Dr. Levitt has more than 24 years of senior management experience. He served as Executive Vice President, Research and Development at Cerimon Pharmaceuticals.

Prior to that, Dr. Levitt was Chief Medical Officer and Head of Clinical and Regulatory Affairs at Dynavax Technologies Corporation, managing clinical trials for four programs and overseeing multi-country regulatory strategies.

He was also Chief Operating Officer and Head of Research and Development at Affymax, Inc., where he spearheaded all aspects of that company’s research, development, and commercialization operations, and he spent six years at Protein Design Labs, Inc., completing his tenure as that firm’s President and Head of Research and Development.

Dr. Levitt’s past experience includes a position as Head of Drug Development at Geron Corporation, and Head of the Cytokine Development Unit and Global Clinical Oncology at Sandoz Pharmaceuticals Ltd., and as Director, Clinical Oncology and Immunology at Hoffmann-LaRoche, Inc.

Dr. Levitt graduated Magna Cum Laude and Phi Beta Kappa with a Bachelor of Arts degree from Brandeis University.

He earned both his M.D. and his Ph.D. in Biology from the University of Chicago Pritzker School of Medicine. He has received 10 major research awards and authored or co-authored nearly 200 papers and abstracts. ■

• Peregrine Pharmaceuticals appoints Mark R. Bamforth to boards
• Endologix appoints John Onopchenko as COO
• Depomed appoints Santosh J. Vetticaden as CSO
• Wells Fargo names Michael Roemer as chief compliance officer
• ARMO BioSciences appoints Joseph Leveque as CMO

---

More inside POST